

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 MADRID

Granada 10 April 2015

RELEVANT FACT NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby puts in knowledge the following information.

The capital increase, which was agreed by the Board of Directors at 19 January 2015 in exercise of the delegation conferred upon it by the General Shareholders' Meeting held on 25 July March 2014, has completely been subscribed. The capital increase has consisted in issuing up 1,387,500 new shares at € 1 of nominal value per each new share thus with an issue premium of 0.40 EURO.

Consequently, the total amount of the capital increase raised € 1,942,500. During the additional period over 1,300,000 share applications have been received.

The new shares are ordinary ones and belong to the same class and series with the same rights and obligations, than those shares currently outstanding.

Press release is enclosed.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

NEURON BIO COMPLETES THE CAPITAL INCREASE SUCCESSFULLY

Neuron Bio (NEU.MC), a biotech company quoting at the Spanish Alternative Market has completely fulfilled the capital increase launched in March.

The capital increase has completely been subscribed arising € 1,942,500. During the additional period over 1,300,000 share applications have been received.

The funds raised will be targeted to the development of the strategic plan of Neuron Bio presented and unanimously approved in the Extraordinary Shareholders' Meeting held the last 24 March. It is focused on the continuation of the compounds development of its product portfolio for nervous system diseases, in the technical development of diagnosis tools of the Alzheimer's disease and in commercial activities aimed at achieving its license.

Neuron Bio also made the commitment with its shareholders to carry out the necessary actions after the capital increase success to incorporate its subsidiary Neol Bio into a regulated capital market also regarding the turnover increase to be achieved in 2015.

The chairman of the company, Fernando Valdivieso expressed his satisfaction with the result of the capital increase, "I am grateful with the confidence that investors placed on the company, with the unanimous support the shareholders gave to the new strategic plan in the Shareholders' Meeting, with all the team of the company that has fulfilled the commitment with the enterprise during ten years, something that is going to continue with the great challenges that it will have to face in this new phase."

Neuron Bio has invested over € 30 million (€ 12.6 million of private funds and € 18.3 of public funds) in the creation of a powerful scientific structure, the development and repurchase to Repsol of its subsidiary Neol Bio and the construction of a new and modern head office. For the period 2015-2018 it is expected to do an additional investment of € 16 million in order to implement its business plan that also includes the creation of a subsidiary in USA, the main market for its products.

For further informatio:

Malena Valdivieso
mvaldivieso@neuronbio.com
Tef.: +34 958 750 598

www.neuronbio.com

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

NOTE FOR EDITORS

About Neuron Bio

Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas.

Its **pharma division** is mainly devoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer's disease.

Its **diagnostic division** develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as in the case of the Alzheimer's disease.

Its **service division** develops research projects as well as consultancy services for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area.

Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 9 patent applications (2 of them recently granted by the European Union and other 1 also granted recently by the US Patent and Trademark Office) and exclusive platforms for drug discovery and development.

Neol Bio, a 100% subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

It has a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects.

Neuron Bio has facilities in Granada and Madrid that are connected with university research centers and is quoted on the Alternative Stock Market (MAB) in Spain.